{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:49:17Z","timestamp":1788785357436,"version":"build-2803163510"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pnpbp.2025.111580","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:44:49Z","timestamp":1765471489000},"page":"111580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neuropharmacological targets for schizophrenia treatment: An update"],"prefix":"10.1016","volume":"144","author":[{"given":"Caroline Araujo Costa","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Eduarda Oliveira","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Jos\u00e9 Coelho","family":"Souza-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Viana","family":"Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneas Andrade","family":"Fontes-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Socorro Ferraz","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2025.111580_bb0005","doi-asserted-by":"crossref","unstructured":"Abekawa T, Ito K, Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedeberg's Arch. Pharmacol. 2006 Dec;374(3):177-93. doi: https:\/\/doi.org\/10.1007\/s00210-006-0115-9. Epub 2006 Nov 14. PMID: 17103144.","DOI":"10.1007\/s00210-006-0115-9"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"14","key":"10.1016\/j.pnpbp.2025.111580_bb0015","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0020","doi-asserted-by":"crossref","unstructured":"Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang DR, Laruelle M, Slifstein M. Increased prefrontal cortical D\u2081 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112. J. Psychopharmacol. 2012 26(6):794-805. doi: https:\/\/doi.org\/10.1177\/0269881111409265. Epub 2011 Jul 18. PMID: 21768159.","DOI":"10.1177\/0269881111409265"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2710.2000.00273.x","article-title":"Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions","volume":"25","author":"Akhondzadeh","year":"2000","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuroscience.2011.05.068","article-title":"Increased desensitization of dopamine D\u2082 receptor-mediated response in the ventral tegmental area in the absence of adenosine A(2A) receptors","volume":"190","author":"Al-Hasani","year":"2011","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/acps.13562","article-title":"Does a history of cannabis use influence onset and course of schizophrenia?","volume":"147","author":"Allebeck","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0040","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)","author":"American Psychiatric Association","year":"2013"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111580_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv016","article-title":"Extensive gray matter volume reduction in treatment-resistant schizophrenia","volume":"18","author":"Anderson","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.biopsych.2014.07.022","article-title":"N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia","volume":"77","author":"Anticevic","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-3956(99)00039-4","article-title":"Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the \u201ctwo hit hypothesis\u201d","volume":"33","author":"Bayer","year":"1999","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111580_bb0065","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","article-title":"Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study","volume":"168","author":"Benros","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.euroneuro.2012.04.015","article-title":"Striatal dopamine D2\/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis","volume":"23","author":"Bloemen","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2015.14101358","article-title":"Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study","volume":"173","author":"Bloomfield","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuropharm.2005.01.024","article-title":"Adenosine receptors co-operate with NMDA preconditioning to protect cerebellar granule cells against glutamate neurotoxicity","volume":"49","author":"Boeck","year":"2005","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0085","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.neuropharm.2011.01.048","article-title":"Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy","volume":"62","author":"Boison","year":"2012","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0090","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells9051077","article-title":"Multiple adenosine-dopamine (A2A-D2 Like) heteroreceptor complexes in the brain and their role in schizophrenia","volume":"9","author":"Borroto-Escuela","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7","article-title":"Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach","volume":"29","author":"Breier","year":"1998","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2006.11.071","article-title":"Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment","volume":"414","author":"Brunstein","year":"2007","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111580_bb0105","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1038\/s41380-022-01649-w","article-title":"Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia","volume":"27","author":"Buck","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0110","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1471-4159.2009.06078.x","article-title":"Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells","volume":"109","author":"Cabello","year":"2009","journal-title":"J. Neurochem."},{"issue":"13","key":"10.1016\/j.pnpbp.2025.111580_bb0115","article-title":"P2X7 receptor-dependent layer-specific changes in neuron-microglia reactivity in the prefrontal cortex of a phencyclidine induced mouse model of schizophrenia","author":"Calovi","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111580_bib782","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/pcn.13892","article-title":"Repurposed antihypertensive drugs for negative symptoms in schizophrenia: A systematic review and meta-analysis","volume":"79","author":"Carnaval","year":"2025","journal-title":"Psychiatry Clin Neurosci."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/mp.2011.31","article-title":"A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior","volume":"17","author":"Carl\u00e9n","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0125","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/sj.npp.1300152","article-title":"Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization","volume":"28","author":"Chen","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0130","first-page":"1","article-title":"The roles of purinergic signaling in psychiatric disorders","volume":"63","author":"Cie\u015blak","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative Symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0140","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0447.2009.01372.x","article-title":"Early intervention in patients at ultra high risk of psychosis: benefits and risks","volume":"119","author":"de Koning","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111580_bb0145","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","article-title":"Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study","volume":"70","author":"de la Fuente-Sandoval","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3940(00)01391-4","article-title":"Long-term potentiation observed upon blockade of adenosine A1 receptors in rat hippocampus is N-methyl-D-aspartate receptor-dependent","volume":"291","author":"de Mendon\u00e7a","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00001756-200303030-00003","article-title":"Up-regulation of striatal adenosine A(2A) receptors in schizophrenia","volume":"14","author":"Deckert","year":"2003","journal-title":"Neuroreport"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111580_bb0160","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0165","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111580_bb0170","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1097\/00001756-200107030-00014","article-title":"Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum","volume":"12","author":"D\u00edaz-Cabiale","year":"2001","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0304-3940(02)00179-9","article-title":"Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors","volume":"324","author":"D\u00edaz-Cabiale","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111580_bb0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2008.12.028","article-title":"A double-blind trial of adjunctive allopurinol for schizophrenia","volume":"109","author":"Dickerson","year":"2009","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0185","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/archpsyc.64.5.532","article-title":"Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia","volume":"64","author":"Dickinson","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2020.09.013","article-title":"Glutamate in schizophrenia: neurodevelopmental perspectives and drug development","volume":"223","author":"Egerton","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0195","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fnhum.2015.00476","article-title":"Immunological findings in psychotic syndromes: a tertiary care hospital\u2019s CSF sample of 180 patients","volume":"9","author":"Endres","year":"2015","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(91)90064-W","article-title":"Postsynaptic dopamine\/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice","volume":"192","author":"Ferr\u00e9","year":"1991","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0205","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00001756-199412300-00020","article-title":"Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors","volume":"6","author":"Ferr\u00e9","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0210","doi-asserted-by":"crossref","unstructured":"Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry. 2013 74(6):400-9. doi: 10.1016\/j.biopsych.2013.03.018. Epub 2013 May 15. PMID: 23683390; PMCID: PMC4018767.","DOI":"10.1016\/j.biopsych.2013.03.018"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.101739","article-title":"A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms","volume":"22","author":"Fleming","year":"2019","journal-title":"Neuroimage Clin."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0220","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/schbul\/sby125","article-title":"Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis","volume":"45","author":"Fraguas","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/biom9060234","article-title":"Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the thalamocortical pathway via the activation of a group III metabotropic glutamate receptor","volume":"9","author":"Fukuyama","year":"2019","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0230","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1755-5949.2009.00126.x","article-title":"Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Fuxe","year":"2010","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"26","key":"10.1016\/j.pnpbp.2025.111580_bb0240","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1523\/JNEUROSCI.0329-15.2015","article-title":"Prefrontal and striatal glutamate differently relate to striatal dopamine: potential regulatory mechanisms of striatal presynaptic dopamine function?","volume":"35","author":"Gleich","year":"2015","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0006-8993(98)00743-4","article-title":"Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum","volume":"806","author":"Go\u0142embiowska","year":"1998","journal-title":"Brain Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111580_bb0250","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.3390\/ijms22094467","article-title":"Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention","volume":"22","author":"Gomes","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/wps.20624","article-title":"Nonsocial and social cognition in schizophrenia: current evidence and future directions","volume":"18","author":"Green","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0260","article-title":"Resting-state gamma-band power alterations in schizophrenia reveal E\/I-balance abnormalities across illness-stages","volume":"7","author":"Grent-\u2019t-Jong","year":"2018","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0265","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2215-0366(23)00025-1","article-title":"Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis","volume":"10","author":"Halstead","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111580_bb0270","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.schres.2008.05.026","article-title":"Variation in the purinergic P2RX(7) receptor gene and schizophrenia","volume":"104","author":"Hansen","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0275","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2013.07.027","article-title":"The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor","volume":"75","author":"Hempel","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111580_bb0280","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2013.06.038","article-title":"Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators","volume":"149","author":"Hirota","year":"2013","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0285","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"43","key":"10.1016\/j.pnpbp.2025.111580_bb0290","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J. Neurosci."},{"issue":"9929","key":"10.1016\/j.pnpbp.2025.111580_bb0295","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"383","author":"Howes","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/archgenpsychiatry.2008.514","article-title":"Elevated striatal dopamine function linked to prodromal signs of schizophrenia","volume":"66","author":"Howes","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111580_bb0305","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Pt 11","key":"10.1016\/j.pnpbp.2025.111580_bb0310","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1093\/brain\/awt264","article-title":"Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study","volume":"136","author":"Howes","year":"2013","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0315","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2021.101993","article-title":"The potential of the P2X7 receptor as a therapeutic target in a sub-chronic PCP-induced rodent model of schizophrenia","volume":"116","author":"Huang","year":"2021","journal-title":"J. Chem. Neuroanat."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111580_bb0325","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0020764020943629","article-title":"The effect of childhood trauma on age of onset in patients with schizophrenia","volume":"66","author":"\u0130nge\u00e7","year":"2020","journal-title":"Int. J. Soc. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0330","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.psc.2020.02.010","article-title":"Neurodevelopmental factors in schizophrenia","volume":"43","author":"Jaaro-Peled","year":"2020","journal-title":"Psychiatr. Clin. North Am."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111580_bb0335","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","article-title":"The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study","volume":"5","author":"Jauhar","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0340","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0345","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2215-0366(15)00098-X","article-title":"D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial","volume":"2","author":"Kantrowitz","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0350","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2025.111580_bb0355","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2015.04.015","article-title":"Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia","volume":"165","author":"Kaster","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0360","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.neuron.2006.01.023","article-title":"Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning","volume":"49","author":"Kellendonk","year":"2006","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0365","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41398-017-0071-9","article-title":"Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience","volume":"8","author":"Kesby","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111580_bb0370","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.biopsych.2008.12.029","article-title":"Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects","volume":"65","author":"Kessler","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0375","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-012-0001-4","article-title":"Cognitive impairment associated with schizophrenia: a review of the humanistic burden","volume":"29","author":"Kitchen","year":"2012","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/srep36680","article-title":"The role of P2X7 receptors in a rodent PCP-induced schizophrenia model","volume":"6","author":"Kov\u00e1nyi","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0385","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41398-022-02253-w","article-title":"Glutamatergic dysfunction in schizophrenia","volume":"12","author":"Kruse","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0390","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111580_bb0395","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ijnp\/pyx063","article-title":"Affinity states of striatal dopamine D2 receptors in antipsychotic-free patients with schizophrenia","volume":"20","author":"Kubota","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0400","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4172\/2155-6105.1000324","article-title":"An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS)","volume":"8","author":"Kumari","year":"2017","journal-title":"J. Addict. Res. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0405","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0006-8993(98)00840-3","article-title":"An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics","volume":"808","author":"Kurumaji","year":"1998","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00213-008-1196-6","article-title":"Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia","volume":"200","author":"Labrie","year":"2008","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1054\/mehy.1999.0003","article-title":"Schizophrenia: a purinergic hypothesis","volume":"54","author":"Lara","year":"2000","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0420","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0425","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/jpm11050388","article-title":"TMS-EEG research to elucidate the pathophysiological neural bases in patients with schizophrenia: a systematic review","volume":"11","author":"Li","year":"2021","journal-title":"J. Pers. Med."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0430","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-020-00135-y","article-title":"Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia","volume":"7","author":"Lintunen","year":"2021","journal-title":"NPJ Schizophr."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111580_bb0440","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/sj.npp.1301356","article-title":"Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat","volume":"32","author":"L\u00f3pez-Gil","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0445","article-title":"Neurobiology of schizophrenia: a comprehensive review","volume":"14","author":"Luvsannyam","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0450","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2023.07.010","article-title":"Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments","volume":"258","author":"Marder","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0460","doi-asserted-by":"crossref","first-page":"115441","DOI":"10.1016\/j.bbr.2025.115441","article-title":"Repeated administration of a subanesthetic dose of ketamine results in impaired motor and cognitive behavior and differential expression of hippocampal P2X1 and P2X7 receptors in adult mice","volume":"482","author":"Mares-Barbosa","year":"2025","journal-title":"Behav. Brain Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111580_bb0465","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.biopsych.2015.02.026","article-title":"Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia","volume":"78","author":"Matos","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0470","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0480","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0485","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0490","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S1121189X00002104","article-title":"Urban birth and risk of schizophrenia: a worrying example of epidemiology where the data are stronger than the hypotheses","volume":"15","author":"McGrath","year":"2006","journal-title":"Epidemiol. Psichiatr. Soc."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0495","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/schbul\/sbaa156","article-title":"Changes in brain glutamate on switching to clozapine in treatment-resistant schizophrenia","volume":"47","author":"McQueen","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0500","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.mp.4000880","article-title":"The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine","volume":"6","author":"Melone","year":"2001","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111580_bb0505","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111580_bb0510","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0515","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0361-9230(95)02144-2","article-title":"Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats","volume":"40","author":"Miller","year":"1996","journal-title":"Brain Res. Bull."},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111580_bb0520","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0525","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/9781118753378.ch104","article-title":"Antipsychotic drugs","author":"Miyamoto","year":"2015","journal-title":"Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0530","doi-asserted-by":"crossref","unstructured":"Mondelli V, Blackman G, Kempton MJ, Pollak TA, Iyegbe C, Valmaggia LR, Amminger P, Barrantes-Vidal N, Bressan R, Van Der Gaag M, De Haan L, Krebs MO, Nordentoft M, Ruhrmann S, Riecher-R\u00f6ssler A, Rutten BPF, Sachs G, Koutsouleris N; EU GEI High Risk Study; McGuire P. Serum immune markers and transition to psychosis in individuals at clinical high risk. Brain Behav. Immun. 2023 110:290-296. doi: https:\/\/doi.org\/10.1016\/j.bbi.2023.03.014. Epub 2023 Mar 20. PMID: 36940754.","DOI":"10.1016\/j.bbi.2023.03.014"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0535","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/eip.12859","article-title":"Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment","volume":"14","author":"Mongan","year":"2020","journal-title":"Early Interv. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0540","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/schbul\/sbz086","article-title":"Adenosine kinase expression in the frontal cortex in schizophrenia","volume":"46","author":"Moody","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0545","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2022.05.022","article-title":"Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: a prospective, pragmatic, semi-randomized trial","volume":"246","author":"M\u00f8rkved","year":"2022","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0550","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0555","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/schbul\/sbx121","article-title":"30 years on: how the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis","volume":"43","author":"Murray","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0560","article-title":"Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review","volume":"2012","author":"Ochoa","year":"2012","journal-title":"Schizophr. Res. Treat."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111580_bb0565","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41386-018-0028-6","article-title":"Cell-subtype-specific changes in adenosine pathways in schizophrenia","volume":"43","author":"O\u2019Donovan","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"28","key":"10.1016\/j.pnpbp.2025.111580_bb0570","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.12998\/wjcc.v9.i28.8295","article-title":"Nutrition, nutritional deficiencies, and schizophrenia: an association worthy of constant reassessment","volume":"9","author":"Onaolapo","year":"2021","journal-title":"World J. Clin. Cases"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0575","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41380-018-0220-4","article-title":"Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis","volume":"24","author":"Orlovska-Waast","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0580","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13651501.2022.2106245","article-title":"Increased NLRP3 inflammasome expression in peripheral blood mononuclear cells of patients with schizophrenia: a case-control study","volume":"27","author":"Ozdamar Unal","year":"2023","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"16","key":"10.1016\/j.pnpbp.2025.111580_bb0585","first-page":"30629","article-title":"Alterations in ventral and dorsal striatal allosteric A2AR-D2R receptor-receptor interactions after amphetamine challenge: relevance for schizophrenia","volume":"S0024-3205","author":"Pintsuk","year":"2016","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0590","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41380-021-01349-x","article-title":"Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis","volume":"27","author":"Plav\u00e9n-Sigray","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0595","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.257","article-title":"Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain","volume":"7","author":"Purves-Tyson","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111580_bb0600","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40263-024-01100-4","article-title":"When, Why and how to re-challenge clozapine in schizophrenia following myocarditis","volume":"38","author":"Qubad","year":"2024","journal-title":"CNS Drugs"},{"issue":"32","key":"10.1016\/j.pnpbp.2025.111580_bb0605","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.2174\/138161212802884861","article-title":"Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies","volume":"18","author":"Rapp","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0610","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neulet.2011.06.011","article-title":"Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801","volume":"500","author":"Roenker","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061278","article-title":"Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes","volume":"8","author":"Rompala","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0620","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cells13010032","article-title":"Adenosine receptor mRNA expression in frontal cortical neurons in schizophrenia","volume":"13","author":"Sahay","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0625","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/syn.20303","article-title":"Psychosis pathways converge via D2high dopamine receptors","volume":"60","author":"Seeman","year":"2006","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0630","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCO.0b013e328017f68e","article-title":"Migration and schizophrenia","volume":"20","author":"Selten","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0635","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WNR.0b013e3283500987","article-title":"Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia","volume":"23","author":"Shan","year":"2012","journal-title":"Neuroreport"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111580_bb0640","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1172\/JCI62378","article-title":"Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia","volume":"122","author":"Shen","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111580_bib781","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/pcn.13872","article-title":"Autoantibodies and Inflammation in Schizophrenia","volume":"79","author":"Shiwaku","year":"2025","journal-title":"Psychiatry Clin Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0645","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/09540260400014401","article-title":"A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders","volume":"16","author":"Shih","year":"2004","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1120532","article-title":"The adenosine hypothesis of schizophrenia into its third decade: from neurochemical imbalance to early life etiological risks","volume":"17","author":"Singer","year":"2023","journal-title":"Front. Cell. Neurosci."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111580_bb0655","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1046\/j.1471-4159.1998.71062454.x","article-title":"Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of \u201cneuroleptic-free\u201d schizophrenics: evidence on reversible up-regulation by typical neuroleptics","volume":"71","author":"Sokolov","year":"1998","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111580_bb0660","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/cells14090650","article-title":"Inflammation in schizophrenia: the role of disordered oscillatory mechanisms","volume":"14","author":"Speers","year":"2025","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111580_bb0665","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11920-019-1091-3","article-title":"Non-Genetic Factors in Schizophrenia","volume":"21","author":"Stilo","year":"2019","journal-title":"Curr Psychiatry Rep."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111580_bb0670","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/mp.2011.171","article-title":"Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology","volume":"17","author":"Stone","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0675","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852924000622","article-title":"What is schizophrenia - symptomatology","volume":"30","author":"Striebel","year":"2024","journal-title":"CNS Spectr."},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111580_bb0680","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies","volume":"60","author":"Sullivan","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3.4","key":"10.1016\/j.pnpbp.2025.111580_bb0685","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2152\/jmi.71.205","article-title":"Schizophrenia and cognitive dysfunction","volume":"71","author":"Takeda","year":"2024","journal-title":"J. Med. Investig."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0690","first-page":"3462","article-title":"Genetics of schizophrenia (Review)","volume":"20","author":"Trifu","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111580_bb0695","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0700","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/jcm13185637","article-title":"Pharmacological treatments of negative symptoms in schizophrenia\u2014an update","volume":"13","author":"Tsapakis","year":"2024","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111580_bb0705","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1399-5618.2009.00752.x","article-title":"Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia","author":"Uezato","year":"2009","journal-title":"Bipolar Disord."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111580_bb0710","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0715","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment","volume":"206","author":"Urig\u00fcen","year":"2009","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0720","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41386-020-00872-9","article-title":"Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia","volume":"46","author":"Valle-Le\u00f3n","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111580_bb0725","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.4","article-title":"Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies","volume":"7","author":"van Kesteren","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jpsychires.2013.12.013","article-title":"Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia","volume":"51","author":"Villar-Men\u00e9ndez","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0735","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10826084.2018.1521430","article-title":"A systematic review of the symptom profile and course of methamphetamine-associated psychosis substance use and misuse","volume":"54","author":"Voce","year":"2019","journal-title":"Subst. Use Misuse"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111580_bb0740","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/s41380-022-01572-0","article-title":"Dopaminergic dysfunction and excitatory\/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment","volume":"27","author":"Wada","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0745","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.schres.2018.06.033","article-title":"Autoimmune diseases are associated with an increased risk of schizophrenia: A nationwide population-based cohort study","volume":"202","author":"Wang","year":"2018","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111580_bb0750","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/mp.2012.137","article-title":"Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia","volume":"18","author":"Weickert","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0755","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00406-013-0479-z","article-title":"Neuropathological changes in the substantia nigra in schizophrenia but not depression","volume":"264","author":"Williams","year":"2014","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111580_bb0760","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","article-title":"Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study","volume":"3","author":"Wimberley","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111580_bb0765","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-011-2315-3","article-title":"Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling","volume":"218","author":"Wonodi","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111580_bb0770","series-title":"Schizophrenia","author":"World Health Organization (WHO)","year":"2022"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111580_bb0775","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(97)01435-0","article-title":"Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex","volume":"341","author":"Yonezawa","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111580_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111166","article-title":"Associations between cytokine levels and cognitive function among individuals at clinical high risk for psychosis","volume":"136","author":"Zhang","year":"2025","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625003343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625003343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:22:38Z","timestamp":1773912158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625003343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":158,"alternative-id":["S0278584625003343"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111580","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropharmacological targets for schizophrenia treatment: An update","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111580"}}